-  INCLUSION CRITERIA:

          -  Patients with biopsy proven (confirmed in the Laboratory of Pathology, CCR) Kaposi
             sarcoma (KS)

          -  KS requiring systemic therapy, with a history of prior therapy:

               -  T1 KS or T0 KS sufficiently widespread that systemic therapy is advisable, or KS
                  affecting quality-of-life due to local symptoms or psychological distress OR

               -  KS patients with an inadequate response to liposomal doxorubicin, paclitaxel,
                  other systemic chemotherapy (either progressive disease or stable disease after 3
                  or more cycles) or immunotherapy (progressive disease)

          -  A wash-out period off treatment of 2 weeks from last chemotherapy and 4 weeks from
             last immunotherapy, other systemic treatment with a biologic agent, or monoclonal
             antibody therapy will be required.

          -  Resolution of toxicity from prior therapy to less than or equal to Grade 1.

          -  At least five measurable cutaneous KS lesions with no previous local radiation,
             surgical or intralesional cytotoxic therapy that would prevent response assessment for
             that lesion.

          -  Measurable disease by the criteria proposed by the AIDS Clinical Trials Group (ACTG)
             Oncology Committee for KS

          -  Patients can be HIV positive or negative.

          -  ART for HIV+ patients for 8 or more weeks prior to entry with an HIV viral load of
             <400 copies/ml at screening and CD4+ T cell count of >50 cells/ (NotEqual)L as this
             may be expected if patients have received several courses of chemotherapy.

          -  Age greater than or equal to18 years.

          -  ECOG performance status less than or equal to 2 (Karnofsky greater than or equal to
             60%).

          -  Patients must have adequate organ and marrow function as defined below:

               -  absolute neutrophil count greater than or equal to 1,500/mcL

               -  platelets greater than or equal to 100,000/mcL

               -  total bilirubin within normal institutional limits; OR <3x institutional ULN for
                  Gilbert s syndrome or HIV protease inhibitors; OR <5x ULN and direct bilirubin <
                  0.7mg/dL for patients on atazanavir-containing HIV regimen

               -  AST(SGOT)/ALT(SGPT) less than or equal to 1.5 X institutional upper limit of
                  normal

               -  hemoglobin greater than or equal to 9g/dL

               -  Creatinine within normal institutional limits OR creatinine clearance >30
                  mL/min/1.73m^2 as estimated by either Cockroft-Gault of 24- hour urine collection
                  for patients with creatinine levels above institutional normal

          -  Normal international normaoized ration (INR), PT less than or equal to 1.5 x ULN and
             activated partial thromboplastin time (aPTT) less than or equal to 1.5 x ULN

          -  The effects of NHS-IL12 and M7824 on the developing human fetus are unknown. For this
             reason, women of child-bearing potential and men must agree to use adequate
             contraception (hormonal or barrier method of birth control; abstinence) prior to study
             entry, during treatment and for at least 4 months after the last dose of treatment and
             agree to inform the treating physician immediately if they become pregnant. Also,
             there is unknown but potential risk for adverse events in nursing infants secondary to
             treatment of the mother with M7824 and/or NHS-IL12, therefore female patients must
             agree to discontinue breastfeeding if treated with these agents.

          -  Ability of subject to understand and the willingness to sign a written informed
             consent document.

        EXCLUSION CRITERIA:

          -  Patients who are receiving any other investigational agents.

          -  Pregnant women are excluded from this study as the effects of NHS-IL12 and M7824 have
             potential teratogenic or abortifacient effects.

          -  Severe KS (such as symptomatic pulmonary KS) that could be life threatening if it
             progressed over 2-4 weeks

          -  Actively bleeding sites caused by visceral KS.

          -  Subjects unwilling to accept blood products as medically indicated

          -  Patients who are actively bleeding and/or requiring transfusions in the 2 weeks
             preceding study entry.

          -  Patients with history of bleeding, diathesis, or recent major bleeding events within a
             period of 4 weeks considered by the investigator as high risk for investigational drug
             treatment.

          -  Patients with any active or recent history (symptomatic in the last 3 months) of a
             known or suspected autoimmune disease (with the exception of diabetes type I,
             vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive
             treatment) or recent history of a syndrome that required systemic corticosteroids
             (10mg daily prednisone or equivalent) or immunosuppressive medications except inhaled
             steroids and adrenal replacement steroids doses up to 10mg daily prednisone
             equivalents are permitted in the absence of active autoimmune disease.Uncontrolled
             opportunistic infections

          -  Active multicentric Castleman disease

          -  Patients with primary effusion lymphoma

          -  History of malignant tumors other than KS, unless:

               -  In complete remission for greater than or equal to 3 years from the time complete
                  remission was first documented or

               -  Resected basal cell or squamous cell carcinoma of the skin or

               -  In situ cervical or anal dysplasia

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to NHS-IL12 and/or M7824 investigational agents used in study.

          -  Active tuberculosis (TB):

               -  Patients who are undergoing first month of therapy (RIPE or equivalent) for
                  active TB or

               -  Patients with TB immune reconstitution syndrome (IRIS) requiring corticosteroids

          -  Patients who have received or will receive a live vaccine within 30 days prior to the
             first administration of study intervention. Seasonal flu vaccines that do not contain
             a live virus are permitted. Locally approved COVID vaccines are permitted.

          -  Uncontrolled substantial intercurrent illness including, but not limited to, ongoing
             or active severe infection, symptomatic congestive heart failure, unstable angina
             pectoris, cardiac arrhythmia, that would limit compliance with study requirements.

          -  Medical or psychiatric illness or social situation that would, in the opinion of the
             investigator, preclude participation in the study or the ability of patients to
             provide informed consent for themselves.

          -  Uncontrolled HBV infection, defined as plasma HBV DNA detectable by PCR

        Note: the following will NOT be exclusionary:

          -  A positive hepatitis B serology indicative of previous immunization (i.e. HBsAb
             positive and HBcAb negative), or a fully resolved acute HBV infection

          -  Patients with chronic HBV suppressed by appropriate antiretroviral therapy with
             activity against HBV, as outlined in DHHS guidelines.

               -  Uncontrolled HCV infection, defined as plasma HCV DNA detectable by PCR

        Note: the following will NOT be exclusionary:

          -  Positive HCV serology but no detectable HCV RNA, indicative of spontaneously cleared
             HCV infection

          -  Patients who have been successfully treated for HCV as long as therapy for HCV has
             been completed.

             -Patients will be excluded from the combination therapy arm if:

          -  they have discontinued prior PD1/L1 blocking agent due to immune mediated adverse
             event(s) OR

          -  they have active non-infectious pneumonitis or a history of steroid requiring
             non-infectious pneumonitis.